Drugs / tributyrin
tributyrin
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05951153 | Aug 2024 → Nov 2025 | disease related to hematopoietic stem cell transplant | Duke University | Withdrawn | No outcome recorded |
| Phase 12 trials | ||||||
| Phase 1 | NCT05446168 | Jul 2022 → Sep 2023 | Parkinson disease | Nicolaas Bohnen, MD, PhD | Terminated | Mixed Stop: Business |
| Phase 1 | NCT00002677 | Aug 1995 → Mar 2003 | prostate cancer | University of Maryland, Baltimore | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT06792500 | Oct 2026 → Mar 2028 expected | Leber plus disease, MELAS syndrome | George Washington University | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07154511 | Nov 2025 → May 2027 expected | Parkinson disease | Prabesh Kanel | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07503548 | Mar → Aug 2026 overdue | diabetes mellitus | Ain Shams University | Not yet recruiting | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tributyrin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05951153 ↗ |
| Known as | Butyrin | ChEMBL registry synonym — accepted as the source's own label CHEMBL118722 ↗ |
| Known as | FEMA NO. 2223 | ChEMBL registry synonym — accepted as the source's own label CHEMBL118722 ↗ |
| Known as | Glycerol Tributyrate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06792500 ↗ |
| Known as | NSC-661583 | ChEMBL registry synonym — accepted as the source's own label CHEMBL118722 ↗ |
| Modality | Other / unclassified | “short-chain fatty acid (SCFA) prodrug tributyrin” NCT05446168 ↗ |
| Route | Oral | “oral tributyrin” NCT00002677 ↗ |